Loading stock data…
$3.67+0.06 (+1.68%)
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
Molecular Partners AG in the Healthcare sector is trading at $3.67 with a market capitalization of $146M. Wall Street consensus targets $10.49 (5 analysts), implying a +185.7% move over the next 12 months. The stock is currently near its 52-week low of $3.52, remaining 12.2% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$13.59M↓ | -$13.44M↓ | -$12.67M↓ | -$11.93M↑ | -$14.70M |
| Net Income | -$13.56M↓ | -$13.14M↓ | -$12.65M↓ | -$11.84M↑ | -$20.40M |
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinic...